Latest Corporate News News
Warner Bros. Discovery Board Rejects Paramount Skydance Tender Offer, Backs Netflix Merger
Warner Bros. Discovery's Board unanimously determined that Paramount Skydance's tender offer launched on December 8, 2025, is not in shareholders' best interests and recommends rejection. The Board reiterates support for the Netflix merger agreement from December 5, offering $23.25 cash plus $4.50 Netflix shares and Discovery Global value, deemed superior.
Netflix welcomed the recommendation, calling it the best for long-term value.
C&S Wholesale Grocers Acquires SpartanNash in $1.77 Billion Deal
C&S Wholesale Grocers acquired SpartanNash for nearly $1.8 billion, one of 2025's top grocery M&A transactions. This bolsters C&S store fleet after its role in the failed Kroger-Albertsons deal divestitures.
The year featured smaller deals reshaping regional power balances.
Alimentation Couche-Tard Closes $1.57 Billion GetGo Acquisition
Circle K owner Alimentation Couche-Tard completed its $1.57 billion purchase of 270 GetGo and WetGo locations in June 2025. To address antitrust issues, it divested 35 gas stations to Majors Management.
This ranks among convenience store sector's biggest M&A moves.
CVB Financial and Heritage Commerce Announce $811 Million Merger
CVB Financial Corp. and Heritage Commerce Corp. agreed to an all-stock merger valued at $811 million, or $13.00 per HTBK share. The deal creates a $22 billion asset California business bank with 75+ branches.
It expands Citizens into the Bay Area while preserving relationship banking.
UWMC Announces Strategic Acquisition of TWO
United Wholesale Mortgage (UWMC) announced acquiring TWO to strengthen positioning, profitability, and cash flow. The deal increases public float by 93% to $2.6 billion and enables synergies in capital markets.
It aligns complementary organizations for growth.
Pfizer Wins Bidding War for Obesity Biotech Metsera in $4.9 Billion Deal
Pfizer acquired Metsera for $4.9 billion after competing with Novo Nordisk, gaining long-acting GLP-1 and amylin assets. The saga topped 2025's most impactful biopharma M&A amid obesity pipeline races.
Pfizer sought external growth after internal failures.
BMS Acquires Orbital Therapeutics for $1.5 Billion in Cell Therapy Bet
Bristol Myers Squibb bought Orbital for $1.5 billion, securing OTX-201 circular RNA therapy for autoimmune disorders. The deal deepens BMS' cell therapy portfolio post anti-BCMA approval.
It contrasts retreats by others from the space.